Medical Education Library

A supplement to Family Practice News.

•TOPIC HIGHLIGHTS/FACULTY

Welcome Letter:
From the Publisher

Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.

Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.

Resources in the Spotlight

Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.

Practical Bits: Diagnostic Tools

Copyright © 2007 Elsevier Inc.

A supplement to Family Practice News.

•TOPIC HIGHLIGHTS/FACULTY

Welcome Letter:
From the Publisher

Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.

Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.

Resources in the Spotlight

Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.

Practical Bits: Diagnostic Tools

Copyright © 2007 Elsevier Inc.

A supplement to Family Practice News.

•TOPIC HIGHLIGHTS/FACULTY

Welcome Letter:
From the Publisher

Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.

Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.

Resources in the Spotlight

Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.

Practical Bits: Diagnostic Tools

Copyright © 2007 Elsevier Inc.

A supplement to Family Practice News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.

•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience

To view the supplement, click the image above.

• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.

Target Audience

This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.

•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience

To view the supplement, click the image above.

• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.

Target Audience

This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.

•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience

To view the supplement, click the image above.

• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.

Target Audience

This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News supported by an educational grant from sanofi-aventis.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.

•Faculty
•Target Audience

To view the supplement, click the image above.

Myth or Fact? Addressing Concerns About the Use of Insulin in Patients With Type 2 Diabetes
Stephen N. Davis, MD, FRCP
Chair, Endocrinology, Diabetes, and Metabolism
Vanderbilt University Medical Center
Nashville, Tenn.

Achieving Lifetime Glycemic Goals in Patients With Type 2 Diabetes
Frank Lavernia, MD
Founder
North Broward Diabetes Center
Pompano Beach, Fla.

Target Audience

This activity is intended for primary care physicians who are involved in the diagnosis and treatment of patients with diabetes.

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News supported by an educational grant from sanofi-aventis.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.

•Faculty
•Target Audience

To view the supplement, click the image above.

Myth or Fact? Addressing Concerns About the Use of Insulin in Patients With Type 2 Diabetes
Stephen N. Davis, MD, FRCP
Chair, Endocrinology, Diabetes, and Metabolism
Vanderbilt University Medical Center
Nashville, Tenn.

Achieving Lifetime Glycemic Goals in Patients With Type 2 Diabetes
Frank Lavernia, MD
Founder
North Broward Diabetes Center
Pompano Beach, Fla.

Target Audience

This activity is intended for primary care physicians who are involved in the diagnosis and treatment of patients with diabetes.

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News supported by an educational grant from sanofi-aventis.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.

•Faculty
•Target Audience

To view the supplement, click the image above.

Myth or Fact? Addressing Concerns About the Use of Insulin in Patients With Type 2 Diabetes
Stephen N. Davis, MD, FRCP
Chair, Endocrinology, Diabetes, and Metabolism
Vanderbilt University Medical Center
Nashville, Tenn.

Achieving Lifetime Glycemic Goals in Patients With Type 2 Diabetes
Frank Lavernia, MD
Founder
North Broward Diabetes Center
Pompano Beach, Fla.

Target Audience

This activity is intended for primary care physicians who are involved in the diagnosis and treatment of patients with diabetes.

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.

Topic Highlights

• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse

• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.

Topic Highlights

• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse

• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.

Topic Highlights

• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse

• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.

Topic Highlights

• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment

• 3-Year Experience With Imiquimod in Vulvar Warts

• Placebo-Controlled Trial in External Anogenital Warts

• Phase III Trials of Imiquimod in Actinic Keratosis

• Observational Long-Term Study of Imiquimod in Actinic Keratosis

• Immune Response Modifier Mechanism of Action

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.

Topic Highlights

• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment

• 3-Year Experience With Imiquimod in Vulvar Warts

• Placebo-Controlled Trial in External Anogenital Warts

• Phase III Trials of Imiquimod in Actinic Keratosis

• Observational Long-Term Study of Imiquimod in Actinic Keratosis

• Immune Response Modifier Mechanism of Action

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.

Topic Highlights

• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment

• 3-Year Experience With Imiquimod in Vulvar Warts

• Placebo-Controlled Trial in External Anogenital Warts

• Phase III Trials of Imiquimod in Actinic Keratosis

• Observational Long-Term Study of Imiquimod in Actinic Keratosis

• Immune Response Modifier Mechanism of Action

Copyright © 2006 Elsevier Inc.

A supplement to Family Practice News.
Supported by an educational grant from Gynecare Worldwide, a division of Ethicon, Inc., a Johnson & Johnson Company.
The articles in this supplement are based on clinical dialogues with the faculty.

•Contents
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

Introduction

Consequences of Heavy Menstrual Bleeding

Types, Patterns, and Causes of Abnormal Uterine Bleeding

• Evaluating the Endometrial Cavity

Treatment Options: Entering the Dialogue

• Medical Therapy

• Surgical Interventions

• Endometrial Ablation Procedures

Considering Cases:

• An Overweight Patient

• A Patient Who Prefers to Avoid Hysterectomy

• A Patient With Postsurgical HMB

Helping Patients Choose

Conclusion

Faculty/Faculty Disclosure Statement

Mary Jane Minkin, MD, FACOG, Chair
Clinical Professor
Department of Obstetrics and Gynecology
Yale University School of Medicine
New Haven, Conn.
Developed a Web site for Gynecare; Speaker's Bureau: Berlex, Inc.

Charles E. Miller, MD, FACOG
Clinical Associate Professor
Department of Obstetrics and Gynecology
University of Illinois at Chicago
Clinical Associate
Department of Obstetrics and Gynecology
University of Chicago
Consultant: Gynecare Worldwide.

Malcolm G. Munro, MD, FRCS(c), FACOG
Professor
Department of Obstetrics and Gynecology
The David Geffen School of Medicine at UCLA
Los Angeles
Attending Staff
Department of Obstetrics and Gynecology
Kaiser Permanente Los Angeles Medical Center
Received Funding for Clinical Grants: Kaiser Research Foundation and Karl Storz Endoscopy-America, Inc.M
Consultant: Boston Scientific Corporation, Gynecare, and Karl Storz Endoscopy.

Robert K. Zurawin, MD, FACOG
Associate Professor
Department of Obstetrics and Gynecology
Baylor College of Medicine
Houston
Consultant/Speaker: Gynecare Worldwide.

Copyright © 2004 by International Medical News Group

A supplement to Family Practice News.
Supported by an educational grant from Gynecare Worldwide, a division of Ethicon, Inc., a Johnson & Johnson Company.
The articles in this supplement are based on clinical dialogues with the faculty.

•Contents
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

Introduction

Consequences of Heavy Menstrual Bleeding

Types, Patterns, and Causes of Abnormal Uterine Bleeding

• Evaluating the Endometrial Cavity

Treatment Options: Entering the Dialogue

• Medical Therapy

• Surgical Interventions

• Endometrial Ablation Procedures

Considering Cases:

• An Overweight Patient

• A Patient Who Prefers to Avoid Hysterectomy

• A Patient With Postsurgical HMB

Helping Patients Choose

Conclusion

Faculty/Faculty Disclosure Statement

Mary Jane Minkin, MD, FACOG, Chair
Clinical Professor
Department of Obstetrics and Gynecology
Yale University School of Medicine
New Haven, Conn.
Developed a Web site for Gynecare; Speaker's Bureau: Berlex, Inc.

Charles E. Miller, MD, FACOG
Clinical Associate Professor
Department of Obstetrics and Gynecology
University of Illinois at Chicago
Clinical Associate
Department of Obstetrics and Gynecology
University of Chicago
Consultant: Gynecare Worldwide.

Malcolm G. Munro, MD, FRCS(c), FACOG
Professor
Department of Obstetrics and Gynecology
The David Geffen School of Medicine at UCLA
Los Angeles
Attending Staff
Department of Obstetrics and Gynecology
Kaiser Permanente Los Angeles Medical Center
Received Funding for Clinical Grants: Kaiser Research Foundation and Karl Storz Endoscopy-America, Inc.M
Consultant: Boston Scientific Corporation, Gynecare, and Karl Storz Endoscopy.

Robert K. Zurawin, MD, FACOG
Associate Professor
Department of Obstetrics and Gynecology
Baylor College of Medicine
Houston
Consultant/Speaker: Gynecare Worldwide.

Copyright © 2004 by International Medical News Group

A supplement to Family Practice News.
Supported by an educational grant from Gynecare Worldwide, a division of Ethicon, Inc., a Johnson & Johnson Company.
The articles in this supplement are based on clinical dialogues with the faculty.

•Contents
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

Introduction

Consequences of Heavy Menstrual Bleeding

Types, Patterns, and Causes of Abnormal Uterine Bleeding

• Evaluating the Endometrial Cavity

Treatment Options: Entering the Dialogue

• Medical Therapy

• Surgical Interventions

• Endometrial Ablation Procedures

Considering Cases:

• An Overweight Patient

• A Patient Who Prefers to Avoid Hysterectomy

• A Patient With Postsurgical HMB

Helping Patients Choose

Conclusion

Faculty/Faculty Disclosure Statement

Mary Jane Minkin, MD, FACOG, Chair
Clinical Professor
Department of Obstetrics and Gynecology
Yale University School of Medicine
New Haven, Conn.
Developed a Web site for Gynecare; Speaker's Bureau: Berlex, Inc.

Charles E. Miller, MD, FACOG
Clinical Associate Professor
Department of Obstetrics and Gynecology
University of Illinois at Chicago
Clinical Associate
Department of Obstetrics and Gynecology
University of Chicago
Consultant: Gynecare Worldwide.

Malcolm G. Munro, MD, FRCS(c), FACOG
Professor
Department of Obstetrics and Gynecology
The David Geffen School of Medicine at UCLA
Los Angeles
Attending Staff
Department of Obstetrics and Gynecology
Kaiser Permanente Los Angeles Medical Center
Received Funding for Clinical Grants: Kaiser Research Foundation and Karl Storz Endoscopy-America, Inc.M
Consultant: Boston Scientific Corporation, Gynecare, and Karl Storz Endoscopy.

Robert K. Zurawin, MD, FACOG
Associate Professor
Department of Obstetrics and Gynecology
Baylor College of Medicine
Houston
Consultant/Speaker: Gynecare Worldwide.

Copyright © 2004 by International Medical News Group